Literature DB >> 33910860

Association Between Serum Alarmin Levels and Disease-specific Indices in Patients With Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis.

Sung Soo Ahn1, Taejun Yoon2, Jason Jungsik Song1,3, Yong-Beom Park1,3, Sang-Won Lee4,3.   

Abstract

BACKGROUND/AIM: We evaluated the relationship between serum alarmin levels and disease-specific indices in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). PATIENTS AND METHODS: Sera and data from 79 patients were utilized. For AAV-specific indices, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index (VDI) were collected and serum levels of four alarmins (hepatoma-derived growth factor, high mobility group box protein 1, S100A9, and S100A12) were measured using enzyme-linked immunosorbent assay. Associations between alarmin levels, AAV-specific indices, and inflammatory laboratory markers were assessed.
RESULTS: S100A9 levels were significantly correlated with C-reactive protein levels (r=0.316, p=0.005) and S100A12 levels correlated with VDI (r=0.232, p=0.040), which was consistent in a subgroup of patients with myeloperoxidase (perinuclear)-ANCA positivity. No other associations were found between alarmin levels and BVAS, FFS, and VDI.
CONCLUSION: The serum S100A12 level was associated with organ damage in AAV, especially in myeloperoxidase (perinuclear)-ANCA-positive patients. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Anti-neutrophil cytoplasmic antibody-associated vasculitis; S100A12; alarmins; biomarker; damage

Mesh:

Substances:

Year:  2021        PMID: 33910860      PMCID: PMC8193346          DOI: 10.21873/invivo.12435

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  35 in total

Review 1.  Alarmins: awaiting a clinical response.

Authors:  James K Chan; Johannes Roth; Joost J Oppenheim; Kevin J Tracey; Thomas Vogl; Marc Feldmann; Nicole Horwood; Jagdeep Nanchahal
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

2.  The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

Authors:  Loïc Guillevin; Christian Pagnoux; Raphaele Seror; Alfred Mahr; Luc Mouthon; Philippe Le Toumelin
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

3.  Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis.

Authors:  A Komatsuda; H Ohtani; H Wakui; K A Chyzh; T Hatakeyama; K Iwamoto; N Maki; T Kimura; J Hitomi; K Sawada
Journal:  Clin Nephrol       Date:  2006-11       Impact factor: 0.975

4.  Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Ruth J Pepper; Juliana B Draibe; Ben Caplin; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks; Peter A Merkel; Alan D Salama
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

Review 5.  Pathogenesis and therapeutic interventions for ANCA-associated vasculitis.

Authors:  Daigo Nakazawa; Sakiko Masuda; Utano Tomaru; Akihiro Ishizu
Journal:  Nat Rev Rheumatol       Date:  2019-02       Impact factor: 20.543

6.  High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus.

Authors:  Deena A Abdulahad; Johanna Westra; Johannes Bijzet; Pieter C Limburg; Cees G M Kallenberg; Marc Bijl
Journal:  Arthritis Res Ther       Date:  2011-05-06       Impact factor: 5.156

7.  Association of serum high mobility group box 1 levels with disease activity and renal involvement in patients with systemic vasculitis.

Authors:  Bin Zhu; Nanfang Li; Qing Zhu; Ting Wu; Mulalibieke Heizati; Guoliang Wang; Xiaoguang Yao; Qin Luo; Shasha Liu; Shanshan Liu; Jing Hong
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

8.  Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies.

Authors:  Ken-Ei Sada; Keiji Ohashi; Yosuke Asano; Keigo Hayashi; Michiko Morishita; Haruki Watanabe; Yoshinori Matsumoto; Shouichi Fujimoto; Yoshinari Takasaki; Kunihiro Yamagata; Shogo Banno; Hiroaki Dobashi; Koichi Amano; Masayoshi Harigai; Yoshihiro Arimura; Hirofumi Makino
Journal:  Arthritis Res Ther       Date:  2020-10-12       Impact factor: 5.156

9.  Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans.

Authors:  Constantin F Urban; David Ermert; Monika Schmid; Ulrike Abu-Abed; Christian Goosmann; Wolfgang Nacken; Volker Brinkmann; Peter R Jungblut; Arturo Zychlinsky
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

10.  Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis.

Authors:  Laura Martinez Valenzuela; Juliana Draibe; Maria Quero Ramos; Xavier Fulladosa Oliveras; Edoardo Melilli; Josep Maria Cruzado Garrit; Juan Torras Ambrós
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.